Back to Explorer

Applications for Premarket Review of New Tobacco Products: Draft Guidance for Industry

DraftCenter for Tobacco Products09/28/2011

Description

This draft guidance is intended to assist persons submitting applications for new tobacco products under section 910 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act; 21 U.S.C. 301 et seq.), as amended by the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) (Public Law 111-31). This draft guidance explains, among other things:

Scope & Applicability

Product Classes

6
New Tobacco Product

Tobacco product not commercially marketed as of February 15, 2007

Smokeless tobacco

Regulated tobacco product category; A category of tobacco products

Roll-your-own tobacco

Class of tobacco product subject to user fees

Cigarette

product category example

Tobacco Product

Subject of the analytical testing method validation; regulatory submission for a tobacco product

Modified Risk Tobacco Product

Relating to the withdrawal of an order for introduction into interstate commerce

Stakeholders

6
Investigational Review Board

Body overseeing clinical study ethics

qualified and appropriately trained investigators

Individuals authorized to receive investigational products.

IRB

Institutional Review Board providing study approvals

Children and adolescents

features may enhance the attractiveness/appeal of your product to children and adolescents

Applicant

Entity submitting development data and knowledge; Entity performing the work process for change

Manufacturer

Entity responsible for submitting NDINs

Regulatory Context

Attributes

4
Appropriate for the protection of the public health

The standard for granting a marketing authorization order

Abuse liability

Potential for drug products to be abused, affecting control status.

Substantially Equivalent

Regulatory status for products similar to a predicate

Shelf Life

Determined based on stability data; Established through stability testing; also called dating period.; Established through formal stability studies; Establishing the period during which a drug product is expected to remain within specifications; Period for drug products; The period during which a drug product is expected to remain within specifications; Duration product remains within acceptance criteria; Period during which product remains within specifications; Established for intermediates pu

Identified Hazards

Hazards

1
Public Health Risk

Correlation of product design attributes with health risks

Related CFR Sections (1)

  • 21CFR25.15§ 25.15 General procedures.

    (a) All applications or petitions requesting agency action require the submission of an EA or a claim of categorical exclusion. A claim of categorical exclusion shall include a statement of compliance with the categorical exclusion criteria and shall state that to the applicant's knowledge, no extraRead full regulation →

Related Warning Letters (10)

  • Clinical Investigator

    Shirish M. Gadgeel, M.D.

    2025-09-09
  • Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

    CCIC Huatongwei International Inspection Co., Ltd.

    2025-08-26
  • Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

    Jiangsu Kerbio Medical Technology Group Co.

    2025-08-26
  • Clinical Investigator

    Mark J. Savant, M.D

    2025-07-15
  • Bioresearch Monitoring Program/Institutional Review Board (IRB)

    United Health Products, Inc.

    2025-05-20
  • Clinical Investigator

    Americo F. Padilla, M.D.

    2025-03-25
  • Institutional Review Board (IRB)

    Armstrong County Memorial Hospital

    2024-11-05
  • Clinical Investigator

    Namita A. Goyal, M.D.

    2024-10-22
  • Institutional Review Board (IRB)

    Louisiana State University Health Science Center IRB

    2024-10-08
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

    Mid-Link Testing Company, Ltd

    2024-09-11

See Also (8)